Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist.
- 20 February 1982
- Vol. 284 (6315), 537-539
- https://doi.org/10.1136/bmj.284.6315.537
Abstract
The new selective 5-HT2 receptor blocking agent ketanserin was given in a dose of 10 mg intravenously to 12 patients with essential hypertension. It caused a distinct fall in supine systemic arterial, right atrial, pulmonary artery, and pulmonary capillary "wedge" pressures. Cardiac output, renal blood flow, and glomerular filtration rate showed no persistent changes. Thus 5-HT2 receptor blockade caused dilatation of both resistance and capacitance vessels and of the renal vascular bed. Heart rate and plasma concentrations of renin and noradrenaline rose after ketanserin. These data suggest that 5-HT may have a role in maintaining high blood pressure.This publication has 11 references indexed in Scilit:
- Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.1981
- Acute blood-pressure-lowering effect of ketanserin.1981
- ACUTE BLOOD-PRESSURE-LOWERING EFFECT OF KETANSERINThe Lancet, 1981
- 5-HT2-RECEPTOR BLOCKADE IN THE TREATMENT OF HEART FAILUREThe Lancet, 1981
- Receptor binding profile of R 41 468, A novel antagonist at 5-HT2 receptorsLife Sciences, 1981
- Supersensitivity of Atherosclerotic Rabbit Aorta to ErgonovineJCI Insight, 1980
- Review of the role of the central serotonergic neuronal system in blood pressure regulation.Hypertension, 1980
- INACTIVE RENIN IN HUMAN PLASMAThe Lancet, 1976
- A sensitive radioenzymatic assay for norepinephrine in tissues and plasmaLife Sciences, 1975
- Abnormal Renal Haemodynamics and Renin Suppression in Hypertensive PatientsClinical Science, 1970